Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710379 · ClinicalTrials.gov registry record · Phase 1
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Adcentrx Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 8
- Study locations
NCT06710379: Recruiting Phase 1 study of Solid Tumors, sponsored by Adcentrx Therapeutics.
NCT06710379 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Adcentrx Therapeutics. The registered enrollment target is 68 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (76% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06710379, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Adcentrx Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 8
- Study locations
Study Summary
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.
Conditions Studied
Interventions
- DRUG ADRX-0405
Study Locations (8)
California
- City of Hope - Duarte
- UCLA - Santa Monica
Texas
- NEXT Austin - Austin
- The University of Texas MD Anderson Cancer Center - Houston
Michigan
- START Midwest - Grand Rapids
Minnesota
- University of Minnesota Masonic Cancer Center - Minneapolis
Utah
- START Mountain Region - West Valley City
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06710379 shows while recruiting
NCT06710379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ADRX-0405 is the first listed.
NCT06710379 lists 8 locations in 6 states (California, Texas, Michigan).
Frequently Asked Questions
What is clinical trial NCT06710379 about?
NCT06710379 is a clinical study titled "A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors". The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.
What is the current status of trial NCT06710379?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2024-12-30. Estimated completion is 2026-12.
What conditions does trial NCT06710379 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06710379?
The interventions under investigation include: ADRX-0405 (DRUG).
Who is sponsoring clinical trial NCT06710379?
This trial is sponsored by Adcentrx Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710379 being conducted?
This trial has 8 study locations across California, Michigan, Minnesota, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06710379's enrollment target sits among peer trials
68 65th of 125 higher than 60 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI